Search | Clinical Trials Finder

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin, Sitagliptin, Placebo for sitagliptin, Placebo for bexagliflozin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Lincoln, California • Long Beach, California • San Dimas, California + 7 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, metformin, sitagliptin, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Buena Park, California • Los Angeles, California • Valencia, California + 15 more

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes Mellitus
Interventions: Sitagliptin; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Canagliflozin, Sitagliptin, Metformin immediate release; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 45
States / cities: Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more

Conditions: Cystic Fibrosis, Prediabetes
Interventions: Sitagliptin; Drug
Lead sponsor: Emory University; Other
Eligibility: 13 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Columbus, Ohio

Conditions: Diabetes
Interventions: MBX-2982, Sitagliptin, placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Los Angeles, California • Las Vegas, Nevada • Binghamton, New York + 1 more

Conditions: Type 1 Diabetes
Interventions: Sitagliptin, Sugar Pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
Interventions: Sitagliptin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes
Interventions: Sitagliptin and Lansoprazole, Placebo; Drug
Lead sponsor: Sanford Health; Other
Eligibility: 11 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota

Conditions: Diabetes Mellitus, Type 2
Interventions: Dutogliptin, Sitagliptin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 86 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 149
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 121 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Fasiglifam (TAK-875), Fasiglifam (TAK-875) Placebo, Sitagliptin, Sitagliptin Placebo, Metformin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 44
States / cities: Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, sitagliptin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 57
States / cities: Huntsville, Alabama • Concord, California • Fresno, California + 48 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, sitagliptin, metformin, sulphonylurea; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more

Conditions: Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions: Sitagliptin, glargine, lispro; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions: Canagliflozin (JNJ-28431754), Sitagliptin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more

Conditions: Pre-diabetes
Interventions: Sitagliptin, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus
Interventions: SYR-472, Placebo, Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 105
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more

Conditions: Glycemic Control
Interventions: Fasiglifam (TAK-875), Sitagliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 58
States / cities: Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 80
States / cities: Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more

Conditions: Type II Diabetes
Interventions: Placebo, Sitagliptin, LEZ763; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg, PF-04937319 - 100mg, Sitagliptin - 100mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 24
States / cities: Anaheim, California • Los Angeles, California • Spring Valley, California + 18 more

Conditions: Diabetes Mellitus Type 2
Interventions: Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 64
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 51
States / cities: Peoria, Arizona • Artesia, California • Concord, California + 48 more

Search by objective public record fields.

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

Sitagliptin in Combination With Metformin and Sulfonylurea

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

Prevention of Cystic Fibrosis Diabetes

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes

Sitagliptin Umbilical Cord Blood Transplant Study

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Incretins in Impaired Fasting Glucose

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)